Valneva SE Sponsored ADR (NASDAQ:VALN - Get Free Report)'s share price gapped down prior to trading on Tuesday . The stock had previously closed at $6.07, but opened at $5.84. Valneva shares last traded at $6.01, with a volume of 2,769 shares changing hands.
Analyst Ratings Changes
Several analysts have recently commented on VALN shares. Guggenheim lowered their price target on shares of Valneva from $15.00 to $14.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. HC Wainwright reiterated a "buy" rating and issued a $17.00 price target on shares of Valneva in a report on Tuesday, April 15th.
Get Our Latest Stock Analysis on Valneva
Valneva Stock Down 1.1%
The company has a current ratio of 2.70, a quick ratio of 2.12 and a debt-to-equity ratio of 0.92. The company's fifty day simple moving average is $6.40 and its two-hundred day simple moving average is $5.98.
Valneva (NASDAQ:VALN - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.27. The firm had revenue of $51.79 million for the quarter, compared to analyst estimates of $41.80 million. Valneva had a negative return on equity of 43.05% and a negative net margin of 43.08%. Equities analysts forecast that Valneva SE Sponsored ADR will post 0.13 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Valneva
A hedge fund recently raised its stake in Valneva stock. Wells Fargo & Company MN increased its holdings in Valneva SE Sponsored ADR (NASDAQ:VALN - Free Report) by 14.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 246,766 shares of the company's stock after acquiring an additional 30,859 shares during the period. Wells Fargo & Company MN owned about 0.30% of Valneva worth $1,079,000 at the end of the most recent reporting period. 11.39% of the stock is owned by hedge funds and other institutional investors.
Valneva Company Profile
(
Get Free Report)
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
Further Reading
Before you consider Valneva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Valneva wasn't on the list.
While Valneva currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
